Felice Verduyn-van Weegen is a Partner in the EQT Life Sciences team. Felice worked for LSP from 2015 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Next to Agomab, Felice is on several company boards for EQT life sciences, including Amolyt pharma and Evommune. Prior to joining LSP, Felice worked as a consultant at McKinsey & Company in Amsterdam, Netherlands. Prior to McKinsey, Felice was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, USA. Felice holds a MSc degree (cum laude) in Neuroscience from VU University Amsterdam and an MBA degree (with distinction) from Columbia Business School in New York.